| Literature DB >> 31495302 |
Koshiro Kanaoka1, Satoshi Okayama1, Michikazu Nakai2, Yoko Sumita2, Kenji Onoue1, Tsunenari Soeda1, Kunihiro Nishimura2, Rika Kawakami1, Hiroyuki Okura1, Yoshihiro Miyamoto2, Satoshi Yasuda2, Hiroyuki Tsutsui3, Issei Komuro4, Hisao Ogawa2, Yoshihiko Saito1.
Abstract
Background Little evidence is available about the number of cardiologists required for appropriate treatment of heart failure (HF). Our objective was to determine the association between the number of cardiologists per cardiology beds for treating patients with acute HF and in-hospital mortality. Methods and Results This was a cross-sectional study, and we used the Japanese Registry of All Cardiac and Vascular Diseases Diagnosis Procedure Combination discharge database. The data of patients with HF on emergency admission from April 1, 2012, to March 31, 2014, were extracted. The patients were categorized into 4 groups by the quartiles of the numbers of cardiologists per 50 cardiovascular beds (first group: median, 4.4 [interquartile range, 3.5-5.0]; second group: median, 6.7 [interquartile range, 6.5-7.5]; third group: median, 9.7 [interquartile range, 8.8-10.1]; and fourth group: median, 16.7 [interquartile range, 14.0-23.8]). Using multilevel mixed-effect logistics regression, we determined adjusted odds ratios for in-hospital mortality. We identified 154 290 patients with HF on emergency admissions. There were 29 626, 36 587, 46 451, and 41 626 patients in the first, second, third, and fourth groups, respectively. HF severity, on the basis of New York Heart Association classification, was similar in the 3 groups. Adjusted odds ratios (95% CIs) for in-hospital mortality were 0.92 (0.82-1.04; P=0.20), 0.82 (0.72-0.92; P<0.001), and 0.70 (0.61-0.80; P<0.001) for the second, third, and fourth groups, respectively. The proportion of medication used, including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β blockers, and mineralocorticoid receptor antagonists, was positively correlated to the number of cardiologists. Conclusions Patients hospitalized for HF in hospitals with larger numbers of cardiologists per cardiovascular beds had lower 30-day mortality.Entities:
Keywords: Japanese Registry of All Cardiac and Vascular Diseases; cardiologist; database; heart failure; quality assessment
Mesh:
Substances:
Year: 2019 PMID: 31495302 PMCID: PMC6818015 DOI: 10.1161/JAHA.119.012282
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Study flow chart.
Hospital Characteristics by Category of Cardiologist Numbers per Cardiovascular Beds
| Characteristics | Total | First Group | Second Group | Third Group | Fourth Group |
|
|---|---|---|---|---|---|---|
| JCS‐certified cardiologists per 50 cardiovascular beds | ||||||
| Median (IQR) | 8.3 (5.7–11.8) | 4.4 (3.5–5.0) | 6.7 (6.5–7.5) | 9.7 (8.8–10.1) | 16.7 (14.0–23.8) | |
| Range | 0.63–68.6 | 0.63–5.7 | 5.8–8.2 | 8.3–11.8 | 11.9–68.6 | |
| No. (%) of hospitals | 770 | 201 (26) | 177 (23) | 203 (26) | 189 (25) | |
| No. of patients with HF/facilities per y | 152 (97–226) | 113 (77–170) | 150.5 (98–215) | 166 (116–242) | 186 (118–275) | <0.001 |
| No. of patients with HF/cardiologists per y | 43 (28–66) | 59 (41–86) | 51 (34–73) | 40 (28–65) | 26 (13–42) | <0.001 |
| Hospital beds | 394 (287–547) | 300 (210–366) | 372 (300–466) | 403 (307–539) | 590 (413–749) | <0.001 |
| Cardiovascular beds | 35 (28–45) | 38 (30–48) | 35 (30–45) | 33 (28–40) | 35 (25–45) | 0.03 |
| JCS‐certified cardiologists | 4 (3–6) | 3 (2–3) | 4 (3–5) | 4 (3–6) | 7 (5–13) | <0.001 |
| JCS‐certified and non–JCS‐certified cardiologists | 5 (4–8) | 3 (2–4) | 5 (4–6) | 7 (5–8) | 11 (8–19) | <0.001 |
| Cardiac surgery facilities, % | 59 | 39 | 51 | 64 | 83 | <0.001 |
| Cardiac intensive care units, % | 82 | 68 | 84 | 86 | 90 | <0.001 |
| Hospital teaching status, % | 82 | 67 | 81 | 88 | 91 | <0.001 |
Continuous variables were expressed as median (IQR) for skewed distributed data. Kruskal‐Wallis test was used to test for mean differences across groups. Categorical variables were presented as frequencies or percentages and were compared using the χ2 test. HF indicates heart failure; IQR, interquartile range; JCS, Japanese Circulation Society.
Patient Characteristics by the Number of Cardiologists per Cardiovascular Beds
| Characteristics | Total | First Group | Second Group | Third Group | Fourth Group |
|
|---|---|---|---|---|---|---|
| JCS‐certified cardiologists per 50 cardiovascular beds | ||||||
| Median (IQR) | 8.3 (5.7–11.8) | 4.4 (3.5–5.0) | 6.7 (6.5–7.5) | 9.7 (8.8–10.1) | 16.7 (14.0–23.8) | |
| Range | 0.63–68.6 | 0.63–5.7 | 5.8–8.2 | 8.3–11.8 | 11.9–68.6 | |
| No. (%) of patients | 150 890 | 29 214 (19) | 35 911 (24) | 45 526 (30) | 40 239 (27) | |
| Age, y | 79±12 | 81±11 | 79±12 | 79±12 | 77±12 | <0.001 |
| Male sex, % | 52 | 48 | 50 | 52 | 54 | <0.001 |
| Charlson comorbidity index | 2 (1–3) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 2 (1–3) | <0.001 |
| Barthel index, % | ||||||
| Low (0–70) | 65 | 66 | 64 | 65 | 64 | <0.001 |
| Middle (75–95) | 9 | 10 | 10 | 10 | 9 | |
| High (100) | 26 | 24 | 26 | 25 | 27 | |
| NYHA classification, % | ||||||
| I | 7 | 6 | 6 | 7 | 7 | <0.001 |
| II | 26 | 25 | 26 | 27 | 25 | |
| III | 34 | 37 | 34 | 32 | 34 | |
| IV | 33 | 34 | 34 | 33 | 34 | |
| Comorbidities, % | ||||||
| Hypertension | 53 | 52 | 53 | 53 | 53 | <0.001 |
| Diabetes mellitus | 34 | 31 | 33 | 34 | 38 | <0.001 |
| Dyslipidemia | 37 | 31 | 35 | 37 | 44 | <0.001 |
| Chronic kidney disease | 12 | 12 | 12 | 11 | 12 | <0.001 |
| Atrial fibrillation | 28 | 30 | 28 | 28 | 27 | <0.001 |
| COPD | 12 | 14 | 12 | 11 | 11 | <0.001 |
| Ambulance use, % | 40 | 34 | 39 | 42 | 44 | <0.001 |
Continuous variables were expressed as mean±SD for normally distributed data or median (IQR) for skewed distributed data. Analysis of variance or Kruskal‐Wallis test was used to test for mean differences across groups. Categorical variables are presented as frequencies or percentages and were compared using the χ2 test. COPD indicates chronic obstructive pulmonary disease; IQR, interquartile range; JCS, Japanese Circulation Society; NYHA, New York Heart Association.
Treatments and Outcomes by the Numbers of Cardiologists per Cardiovascular Beds
| Variable | Total | First Group | Second Group | Third Group | Fourth Group |
|
|---|---|---|---|---|---|---|
| JCS‐certified cardiologists per 50 cardiovascular beds | ||||||
| Median (IQR) | 8.3 (5.7–11.8) | 4.4 (3.5–5.0) | 6.7 (6.5–7.5) | 9.7 (8.8–10.1) | 16.7 (14.0–23.8) | |
| Range | 0.63–68.6 | 0.63–5.7 | 5.8–8.2 | 8.3–11.8 | 11.9–68.6 | |
| No. (%) of patients | 150 890 | 29 214 (19) | 35 911 (24) | 45 526 (30) | 40 239 (27) | |
| Medication, % | ||||||
| ACE inhibitors or ARBs | 60 | 56 | 60 | 60 | 67 | <0.001 |
| β Blockers | 56 | 48 | 53 | 57 | 65 | <0.001 |
| Mineralocorticoid receptor antagonists | 48 | 46 | 46 | 48 | 53 | <0.001 |
| Calcium channel blockers | 37 | 34 | 35 | 36 | 39 | <0.001 |
| Statins | 29 | 24 | 27 | 29 | 35 | <0.001 |
| Oral hypoglycemic agents | 19 | 17 | 19 | 19 | 21 | <0.001 |
| Loop diuretics | 88 | 86 | 88 | 87 | 89 | <0.001 |
| Thiazide | 11 | 9 | 10 | 11 | 13 | <0.001 |
| Tolvaptan | 12 | 10 | 12 | 11 | 12 | <0.001 |
| Cardiac rehabilitation | 25 | 19 | 20 | 25 | 34 | <0.001 |
| Device use and operation, % | ||||||
| Respirator | 19 | 15 | 18 | 19 | 23 | <0.001 |
| IABP | 0.8 | 0.3 | 0.7 | 1 | 1.2 | <0.001 |
| VA‐ECMO | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | <0.001 |
| CRRT | 1.5 | 1.3 | 1.5 | 1.4 | 1.6 | <0.001 |
| PCI | 4.3 | 3.5 | 3.9 | 4.5 | 4.9 | <0.001 |
| Ablation | 0.2 | 0.1 | 0.2 | 0.2 | 0.3 | <0.001 |
| Length of hospital stay, days | 18 (11–27) | 19 (12–31) | 18 (12–29) | 17 (11–26) | 17 (11–25) | <0.001 |
| Hospitalization cost, $ | 7133 (4786–11 156) | 6771 (4543–10 522) | 6890 (4626–10 709) | 7141 (4808–11 126) | 7627 (5099–12 121) | <0.001 |
| Discharge destination, % | ||||||
| Home | 78 | 75 | 78 | 79 | 80 | <0.001 |
| Other hospitals | 9 | 8 | 8 | 9 | 10 | |
| Nursing homes | 4 | 5 | 4 | 3 | 2 | |
| In‐hospital death | 10 | 12 | 10 | 9 | 7 | |
Continuous variables were expressed as median (IQR) for skewed distributed data. Kruskal‐Wallis test was used to test for mean differences across groups. Categorical variables are presented as frequencies or percentages and were compared using the χ2 test. ACE indicates angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; CRRT, continuous renal replacement therapy; VA‐ECMO, venoarterial‐extracorporeal membrane oxygenation; IABP, intra‐aortic balloon pumping; IQR, interquartile range; JCS, Japanese Circulation Society; PCI, percutaneous coronary intervention. $1=¥110.
Figure 2The number of cardiologists and in‐hospital mortality for acute heart failure. Model includes age (per 10 years), sex, Charlson comorbidity index, New York Heart Association classification, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease, atrial fibrillation, cardiac surgery, coronary care unit, hospital teaching status, and ambulance use. OR indicates odds ratio.
Adjusted In‐Hospital Medical Treatments for Patients With HF
| Group | Numbers of Cardiologists per 50 Cardiovascular Beds | β Blockers | ACE Inhibitors or ARBs | MRAs | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| OR | 95% CI |
| ||
| First | 0.63–5.7 | 1 | Reference | 1 | Reference | 1 | Reference | |||
| Second | 5.8–8.2 | 1.09 | 0.97–1.22 | 0.15 | 1.04 | 0.92–1.17 | 0.54 | 0.97 | 0.87–1.08 | 0.59 |
| Third | 8.3–11.8 | 1.23 | 1.09–1.38 | <0.001 | 1.03 | 0.91–1.16 | 0.62 | 1.08 | 0.97–1.21 | 0.17 |
| Fourth | 11.9–68.6 | 1.59 | 1.41–1.81 | <0.001 | 1.38 | 1.20–1.58 | <0.001 | 1.27 | 1.13–1.44 | <0.001 |
Model includes age (per 10 years), sex, Charlson comorbidity index, Barthel index, New York Heart Association classification, hypertension, hyperlipidemia, diabetes mellitus, chronic kidney disease, atrial fibrillation, cardiac surgery, coronary care unit, hospital teaching status, and ambulance use. ACE indicates angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; HF, heart failure; MRA, mineralocorticoid receptor antagonist; OR, odds ratio.